Review



choline transporter 1  (Proteintech)


Bioz Verified Symbol Proteintech is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Proteintech choline transporter 1
    Choline Transporter 1, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 3 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/choline transporter 1/product/Proteintech
    Average 93 stars, based on 3 article reviews
    choline transporter 1 - by Bioz Stars, 2026-05
    93/100 stars

    Images



    Similar Products

    90
    Enamine Ltd abc type glycine betaine transport system jcvi choline abc transporter substratebinding protein pbp2 chox periplasmic binding protein
    Abc Type Glycine Betaine Transport System Jcvi Choline Abc Transporter Substratebinding Protein Pbp2 Chox Periplasmic Binding Protein, supplied by Enamine Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/abc type glycine betaine transport system jcvi choline abc transporter substratebinding protein pbp2 chox periplasmic binding protein/product/Enamine Ltd
    Average 90 stars, based on 1 article reviews
    abc type glycine betaine transport system jcvi choline abc transporter substratebinding protein pbp2 chox periplasmic binding protein - by Bioz Stars, 2026-05
    90/100 stars
      Buy from Supplier

    93
    Proteintech choline transporter 1
    Choline Transporter 1, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/choline transporter 1/product/Proteintech
    Average 93 stars, based on 1 article reviews
    choline transporter 1 - by Bioz Stars, 2026-05
    93/100 stars
      Buy from Supplier

    90
    Thermo Fisher high-affinity choline transporter (slc5a7/cht1) antibody
    High Affinity Choline Transporter (Slc5a7/Cht1) Antibody, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/high-affinity choline transporter (slc5a7/cht1) antibody/product/Thermo Fisher
    Average 90 stars, based on 1 article reviews
    high-affinity choline transporter (slc5a7/cht1) antibody - by Bioz Stars, 2026-05
    90/100 stars
      Buy from Supplier

    90
    Chata Biosystems high-affinity choline transporter
    High Affinity Choline Transporter, supplied by Chata Biosystems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/high-affinity choline transporter/product/Chata Biosystems
    Average 90 stars, based on 1 article reviews
    high-affinity choline transporter - by Bioz Stars, 2026-05
    90/100 stars
      Buy from Supplier

    93
    Proteintech choline transporter
    Fig. 4. Enhanced tumor choline uptake through choline transporters. (A) Haematoxylin and eosin (H&E) stained image and mass spectrometry images of clinical lung cancer tissue. Histograms displayed the intensity of corresponding metabolites in paracancerous and cancerous areas (n ¼ 4 patients). The area drawn by the red and blue line refers to the cancerous area and paracancerous area, respectively. (B) H&E stained image and D9-choline ion image of lung cancer tissue at 4 h after dosing D9-choline to Lewis lung cancer (LLC) mouse. Histograms displayed the intensity of D9-choline in paracancerous and cancerous areas (n ¼ 3 mice). The area drawn by the red and blue line refers to the cancerous area and paracancerous area, respectively. (C) Intensity ratio of D9-choline of cancerous to paracancerous areas over time (n ¼ 3 mice). (D) Western blot analysis of choline transportation related protein expression in different cell lines. (E) Relative mRNA expression of choline <t>transporter-like</t> protein 1 (CTL1) in cancerous (n ¼ 535 patients) and paracancerous tissues (n ¼ 59 patients) of lung cancer patients. (F) Kaplan-Meier survival analysis comparing the overall survival in lung cancer patients with low CTL1 expression (n ¼ 227 patients) versus those with high CTL1 expression (n ¼ 267 patients). Gene expression and survival time data from the Cancer Genome Atlas. Mean ± standard deviation (SD), **P < 0.01, ***P < 0.001. PC: phosphatidylcholine. OCT1/2: organic cation transporter 1/2.
    Choline Transporter, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/choline transporter/product/Proteintech
    Average 93 stars, based on 1 article reviews
    choline transporter - by Bioz Stars, 2026-05
    93/100 stars
      Buy from Supplier

    90
    Thermo Fisher choline transporter-like protein 1 pa5-90449 antibody
    Fig. 4. Enhanced tumor choline uptake through choline transporters. (A) Haematoxylin and eosin (H&E) stained image and mass spectrometry images of clinical lung cancer tissue. Histograms displayed the intensity of corresponding metabolites in paracancerous and cancerous areas (n ¼ 4 patients). The area drawn by the red and blue line refers to the cancerous area and paracancerous area, respectively. (B) H&E stained image and D9-choline ion image of lung cancer tissue at 4 h after dosing D9-choline to Lewis lung cancer (LLC) mouse. Histograms displayed the intensity of D9-choline in paracancerous and cancerous areas (n ¼ 3 mice). The area drawn by the red and blue line refers to the cancerous area and paracancerous area, respectively. (C) Intensity ratio of D9-choline of cancerous to paracancerous areas over time (n ¼ 3 mice). (D) Western blot analysis of choline transportation related protein expression in different cell lines. (E) Relative mRNA expression of choline <t>transporter-like</t> protein 1 (CTL1) in cancerous (n ¼ 535 patients) and paracancerous tissues (n ¼ 59 patients) of lung cancer patients. (F) Kaplan-Meier survival analysis comparing the overall survival in lung cancer patients with low CTL1 expression (n ¼ 227 patients) versus those with high CTL1 expression (n ¼ 267 patients). Gene expression and survival time data from the Cancer Genome Atlas. Mean ± standard deviation (SD), **P < 0.01, ***P < 0.001. PC: phosphatidylcholine. OCT1/2: organic cation transporter 1/2.
    Choline Transporter Like Protein 1 Pa5 90449 Antibody, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/choline transporter-like protein 1 pa5-90449 antibody/product/Thermo Fisher
    Average 90 stars, based on 1 article reviews
    choline transporter-like protein 1 pa5-90449 antibody - by Bioz Stars, 2026-05
    90/100 stars
      Buy from Supplier

    90
    Cambridge Isotope Laboratories mitochondrial transport buffer (kpbs, 10mmhepes, 0.5mmegta, ph 7.35) supplemented with 3mg/l [1,2-13c2] choline chloride
    Fig. 4. Enhanced tumor choline uptake through choline transporters. (A) Haematoxylin and eosin (H&E) stained image and mass spectrometry images of clinical lung cancer tissue. Histograms displayed the intensity of corresponding metabolites in paracancerous and cancerous areas (n ¼ 4 patients). The area drawn by the red and blue line refers to the cancerous area and paracancerous area, respectively. (B) H&E stained image and D9-choline ion image of lung cancer tissue at 4 h after dosing D9-choline to Lewis lung cancer (LLC) mouse. Histograms displayed the intensity of D9-choline in paracancerous and cancerous areas (n ¼ 3 mice). The area drawn by the red and blue line refers to the cancerous area and paracancerous area, respectively. (C) Intensity ratio of D9-choline of cancerous to paracancerous areas over time (n ¼ 3 mice). (D) Western blot analysis of choline transportation related protein expression in different cell lines. (E) Relative mRNA expression of choline <t>transporter-like</t> protein 1 (CTL1) in cancerous (n ¼ 535 patients) and paracancerous tissues (n ¼ 59 patients) of lung cancer patients. (F) Kaplan-Meier survival analysis comparing the overall survival in lung cancer patients with low CTL1 expression (n ¼ 227 patients) versus those with high CTL1 expression (n ¼ 267 patients). Gene expression and survival time data from the Cancer Genome Atlas. Mean ± standard deviation (SD), **P < 0.01, ***P < 0.001. PC: phosphatidylcholine. OCT1/2: organic cation transporter 1/2.
    Mitochondrial Transport Buffer (Kpbs, 10mmhepes, 0.5mmegta, Ph 7.35) Supplemented With 3mg/L [1,2 13c2] Choline Chloride, supplied by Cambridge Isotope Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mitochondrial transport buffer (kpbs, 10mmhepes, 0.5mmegta, ph 7.35) supplemented with 3mg/l [1,2-13c2] choline chloride/product/Cambridge Isotope Laboratories
    Average 90 stars, based on 1 article reviews
    mitochondrial transport buffer (kpbs, 10mmhepes, 0.5mmegta, ph 7.35) supplemented with 3mg/l [1,2-13c2] choline chloride - by Bioz Stars, 2026-05
    90/100 stars
      Buy from Supplier

    90
    Synaptic Systems rabbit anti-vesicle associated choline transporter (vacht)
    Fig. 4. Enhanced tumor choline uptake through choline transporters. (A) Haematoxylin and eosin (H&E) stained image and mass spectrometry images of clinical lung cancer tissue. Histograms displayed the intensity of corresponding metabolites in paracancerous and cancerous areas (n ¼ 4 patients). The area drawn by the red and blue line refers to the cancerous area and paracancerous area, respectively. (B) H&E stained image and D9-choline ion image of lung cancer tissue at 4 h after dosing D9-choline to Lewis lung cancer (LLC) mouse. Histograms displayed the intensity of D9-choline in paracancerous and cancerous areas (n ¼ 3 mice). The area drawn by the red and blue line refers to the cancerous area and paracancerous area, respectively. (C) Intensity ratio of D9-choline of cancerous to paracancerous areas over time (n ¼ 3 mice). (D) Western blot analysis of choline transportation related protein expression in different cell lines. (E) Relative mRNA expression of choline <t>transporter-like</t> protein 1 (CTL1) in cancerous (n ¼ 535 patients) and paracancerous tissues (n ¼ 59 patients) of lung cancer patients. (F) Kaplan-Meier survival analysis comparing the overall survival in lung cancer patients with low CTL1 expression (n ¼ 227 patients) versus those with high CTL1 expression (n ¼ 267 patients). Gene expression and survival time data from the Cancer Genome Atlas. Mean ± standard deviation (SD), **P < 0.01, ***P < 0.001. PC: phosphatidylcholine. OCT1/2: organic cation transporter 1/2.
    Rabbit Anti Vesicle Associated Choline Transporter (Vacht), supplied by Synaptic Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit anti-vesicle associated choline transporter (vacht)/product/Synaptic Systems
    Average 90 stars, based on 1 article reviews
    rabbit anti-vesicle associated choline transporter (vacht) - by Bioz Stars, 2026-05
    90/100 stars
      Buy from Supplier

    90
    Inherited Neuropathies Consortium choline transporter
    Fig. 4. Enhanced tumor choline uptake through choline transporters. (A) Haematoxylin and eosin (H&E) stained image and mass spectrometry images of clinical lung cancer tissue. Histograms displayed the intensity of corresponding metabolites in paracancerous and cancerous areas (n ¼ 4 patients). The area drawn by the red and blue line refers to the cancerous area and paracancerous area, respectively. (B) H&E stained image and D9-choline ion image of lung cancer tissue at 4 h after dosing D9-choline to Lewis lung cancer (LLC) mouse. Histograms displayed the intensity of D9-choline in paracancerous and cancerous areas (n ¼ 3 mice). The area drawn by the red and blue line refers to the cancerous area and paracancerous area, respectively. (C) Intensity ratio of D9-choline of cancerous to paracancerous areas over time (n ¼ 3 mice). (D) Western blot analysis of choline transportation related protein expression in different cell lines. (E) Relative mRNA expression of choline <t>transporter-like</t> protein 1 (CTL1) in cancerous (n ¼ 535 patients) and paracancerous tissues (n ¼ 59 patients) of lung cancer patients. (F) Kaplan-Meier survival analysis comparing the overall survival in lung cancer patients with low CTL1 expression (n ¼ 227 patients) versus those with high CTL1 expression (n ¼ 267 patients). Gene expression and survival time data from the Cancer Genome Atlas. Mean ± standard deviation (SD), **P < 0.01, ***P < 0.001. PC: phosphatidylcholine. OCT1/2: organic cation transporter 1/2.
    Choline Transporter, supplied by Inherited Neuropathies Consortium, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/choline transporter/product/Inherited Neuropathies Consortium
    Average 90 stars, based on 1 article reviews
    choline transporter - by Bioz Stars, 2026-05
    90/100 stars
      Buy from Supplier

    Image Search Results


    Fig. 4. Enhanced tumor choline uptake through choline transporters. (A) Haematoxylin and eosin (H&E) stained image and mass spectrometry images of clinical lung cancer tissue. Histograms displayed the intensity of corresponding metabolites in paracancerous and cancerous areas (n ¼ 4 patients). The area drawn by the red and blue line refers to the cancerous area and paracancerous area, respectively. (B) H&E stained image and D9-choline ion image of lung cancer tissue at 4 h after dosing D9-choline to Lewis lung cancer (LLC) mouse. Histograms displayed the intensity of D9-choline in paracancerous and cancerous areas (n ¼ 3 mice). The area drawn by the red and blue line refers to the cancerous area and paracancerous area, respectively. (C) Intensity ratio of D9-choline of cancerous to paracancerous areas over time (n ¼ 3 mice). (D) Western blot analysis of choline transportation related protein expression in different cell lines. (E) Relative mRNA expression of choline transporter-like protein 1 (CTL1) in cancerous (n ¼ 535 patients) and paracancerous tissues (n ¼ 59 patients) of lung cancer patients. (F) Kaplan-Meier survival analysis comparing the overall survival in lung cancer patients with low CTL1 expression (n ¼ 227 patients) versus those with high CTL1 expression (n ¼ 267 patients). Gene expression and survival time data from the Cancer Genome Atlas. Mean ± standard deviation (SD), **P < 0.01, ***P < 0.001. PC: phosphatidylcholine. OCT1/2: organic cation transporter 1/2.

    Journal: Journal of pharmaceutical analysis

    Article Title: Discovering metabolic vulnerability using spatially resolved metabolomics for antitumor small molecule-drug conjugates development as a precise cancer therapy strategy.

    doi: 10.1016/j.jpha.2023.02.010

    Figure Lengend Snippet: Fig. 4. Enhanced tumor choline uptake through choline transporters. (A) Haematoxylin and eosin (H&E) stained image and mass spectrometry images of clinical lung cancer tissue. Histograms displayed the intensity of corresponding metabolites in paracancerous and cancerous areas (n ¼ 4 patients). The area drawn by the red and blue line refers to the cancerous area and paracancerous area, respectively. (B) H&E stained image and D9-choline ion image of lung cancer tissue at 4 h after dosing D9-choline to Lewis lung cancer (LLC) mouse. Histograms displayed the intensity of D9-choline in paracancerous and cancerous areas (n ¼ 3 mice). The area drawn by the red and blue line refers to the cancerous area and paracancerous area, respectively. (C) Intensity ratio of D9-choline of cancerous to paracancerous areas over time (n ¼ 3 mice). (D) Western blot analysis of choline transportation related protein expression in different cell lines. (E) Relative mRNA expression of choline transporter-like protein 1 (CTL1) in cancerous (n ¼ 535 patients) and paracancerous tissues (n ¼ 59 patients) of lung cancer patients. (F) Kaplan-Meier survival analysis comparing the overall survival in lung cancer patients with low CTL1 expression (n ¼ 227 patients) versus those with high CTL1 expression (n ¼ 267 patients). Gene expression and survival time data from the Cancer Genome Atlas. Mean ± standard deviation (SD), **P < 0.01, ***P < 0.001. PC: phosphatidylcholine. OCT1/2: organic cation transporter 1/2.

    Article Snippet: Antibodies were purchased from Invitrogen (Thermo Fisher Scientific): choline transporter-like protein 1 (CTL1, PA5-90449), carboxylesterase (CES, PA5-109518); and Proteintech (Wuhan, China): organic cation transporter 1 (OCT1, 24617-1-AP), OCT2 (13594-1-AP).

    Techniques: Staining, Mass Spectrometry, Western Blot, Expressing, Gene Expression, Standard Deviation